Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Calpain inhibition preserves myocardial structure and function following myocardial infarction.

Mani SK, Balasubramanian S, Zavadzkas JA, Jeffords LB, Rivers WT, Zile MR, Mukherjee R, Spinale FG, Kuppuswamy D.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1744-51. doi: 10.1152/ajpheart.00338.2009. Epub 2009 Sep 4.

2.

In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium.

Mani SK, Shiraishi H, Balasubramanian S, Yamane K, Chellaiah M, Cooper G, Banik N, Zile MR, Kuppuswamy D.

Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H314-26. doi: 10.1152/ajpheart.00085.2008. Epub 2008 May 16.

3.

Sepiapterin enhances angiogenesis and functional recovery in mice after myocardial infarction.

Shimazu T, Otani H, Yoshioka K, Fujita M, Okazaki T, Iwasaka T.

Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H2061-72. doi: 10.1152/ajpheart.00525.2011. Epub 2011 Sep 2.

PMID:
21890687
4.

Chronic urocortin 2 administration improves cardiac function and ameliorates cardiac remodeling after experimental myocardial infarction.

Ellmers LJ, Scott NJ, Cameron VA, Richards AM, Rademaker MT.

J Cardiovasc Pharmacol. 2015 Mar;65(3):269-75. doi: 10.1097/FJC.0000000000000190.

PMID:
25658462
5.

The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis.

Li X, Luo R, Jiang R, Meng X, Wu X, Zhang S, Hua W.

BMC Cardiovasc Disord. 2013 Feb 20;13:8. doi: 10.1186/1471-2261-13-8.

6.

Activity profile of calpains I and II in chronically infarcted rat myocardium--influence of the calpain inhibitor CAL 9961.

Sandmann S, Prenzel F, Shaw L, Schauer R, Unger T.

Br J Pharmacol. 2002 Apr;135(8):1951-8.

7.

A new calpain inhibitor protects left ventricular dysfunction induced by mild ischemia-reperfusion in in situ rat hearts.

Takeshita D, Tanaka M, Mitsuyama S, Yoshikawa Y, Zhang GX, Obata K, Ito H, Taniguchi S, Takaki M.

J Physiol Sci. 2013 Mar;63(2):113-23. doi: 10.1007/s12576-012-0243-6. Epub 2012 Dec 16.

PMID:
23242912
8.

Cyclosporin A in left ventricular remodeling after myocardial infarction.

Kholmukhamedov A, Logdon C, Hu J, McKinney RA, Spinale FG, Lemasters JJ, Mukherjee R.

Am J Physiol Heart Circ Physiol. 2014 Jan 1;306(1):H53-9. doi: 10.1152/ajpheart.00079.2013. Epub 2013 Oct 25.

9.

Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts.

Du J, Zhang L, Wang Z, Yano N, Zhao YT, Wei L, Dubielecka-Szczerba P, Liu PY, Zhuang S, Qin G, Zhao TC.

Am J Physiol Cell Physiol. 2016 Feb 15;310(4):C270-83. doi: 10.1152/ajpcell.00194.2015. Epub 2016 Jan 6.

10.

Effects of erythropoietin on cardiac remodeling after myocardial infarction.

Nishiya D, Omura T, Shimada K, Matsumoto R, Kusuyama T, Enomoto S, Iwao H, Takeuchi K, Yoshikawa J, Yoshiyama M.

J Pharmacol Sci. 2006 May;101(1):31-9.

11.

Early upregulation of myocardial CXCR4 expression is critical for dimethyloxalylglycine-induced cardiac improvement in acute myocardial infarction.

Mayorga M, Kiedrowski M, Shamhart P, Forudi F, Weber K, Chilian WM, Penn MS, Dong F.

Am J Physiol Heart Circ Physiol. 2016 Jan 1;310(1):H20-8. doi: 10.1152/ajpheart.00449.2015. Epub 2015 Oct 30.

PMID:
26519029
12.

Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion.

Tarkia M, Stark C, Haavisto M, Kentala R, Vähäsilta T, Savunen T, Strandberg M, Saunavaara V, Tolvanen T, Teräs M, Pietilä M, Nyman L, Duvall E, Saukko P, Levijoki J, Roivainen A, Saraste A, Knuuti J.

Heart. 2016 Mar;102(6):465-71. doi: 10.1136/heartjnl-2015-308137. Epub 2016 Jan 13.

PMID:
26762238
13.

Qiliqiangxin improves cardiac function and attenuates cardiac remodeling in rats with experimental myocardial infarction.

Wang J, Zhou J, Ding X, Zhu L, Jiang K, Fu M, Wang S, Hu K, Ge J.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):6596-606. eCollection 2015.

14.

SPARC mediates early extracellular matrix remodeling following myocardial infarction.

McCurdy SM, Dai Q, Zhang J, Zamilpa R, Ramirez TA, Dayah T, Nguyen N, Jin YF, Bradshaw AD, Lindsey ML.

Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H497-505. doi: 10.1152/ajpheart.01070.2010. Epub 2011 May 20.

16.

Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction.

Sam F, Sawyer DB, Xie Z, Chang DL, Ngoy S, Brenner DA, Siwik DA, Singh K, Apstein CS, Colucci WS.

Circ Res. 2001 Aug 17;89(4):351-6.

17.

Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.

Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Silljé HH, de Boer RA.

Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H459-68. doi: 10.1152/ajpheart.00054.2011. Epub 2011 May 13.

PMID:
21572014
18.
19.

Impairment of cardiac function and remodeling induced by myocardial infarction in rats are attenuated by the nonpeptide angiotensin-(1-7) analog AVE 0991.

Zeng WT, Chen WY, Leng XY, Tang LL, Sun XT, Li CL, Dai G.

Cardiovasc Ther. 2012 Jun;30(3):152-61. doi: 10.1111/j.1755-5922.2010.00255.x. Epub 2010 Dec 19.

PMID:
21167013
20.

Neuroprotective effects of MAPK/ERK1/2 and calpain inhibitors on lactacystin-induced cell damage in primary cortical neurons.

Jantas D, Lorenc-Koci E, Kubera M, Lason W.

Neurotoxicology. 2011 Dec;32(6):845-56. doi: 10.1016/j.neuro.2011.05.013. Epub 2011 Jun 1.

PMID:
21683092

Supplemental Content

Support Center